A broad overview of patient-support programs should be a first step in weighing whether these programs deliver value for patients in return for their cost to the health system, says a researcher.
Grail announced a step that may help move the company closer to securing Medicare reimbursement for its Galleri multicancer blood test, sold in the US since 2021.
In a new data analysis, Harvard researchers find that insulin manufacturers have filed multiple patents on delivery devices following the original insulin product approval.